On January 6, 2020 Transcenta Holding (Transcenta) reported that Co-founder & CEO Dr. Xueming Qian will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020, at 14:30 PST in Golden Gate room at Westin St. Francis, San Francisco (Press release, Transcenta, JAN 6, 2020, View Source [SID1234552758]). Dr. Xueming Qian will share the company’s latest development and clinical progresses made to the audience and potential investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Merged by MabSpace and HJB in January 2019, Transcenta is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacturing. In the past year, Transcenta has made significant progresses, e.g. it has built a complimentary team with extensive global industrial experience with the addition of multiple seasoned clinical development leaders, assembled a robust pipeline with over 10 innovative molecules in oncology, bone disorders, nephrology, in-licensed a phase 2 completed anti-sclerostin therapeutic program Blosozumab for severe osteoporosis, and adopted integrated continuous process and manufacturing in its Hangzhou facility to achieve low cost of goods.